Arve Capital
VC Fund
Arve Capital is a VC fund focused on Health Care and Software. ARVE Capital
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Arve Capital invests in
Stages Arve Capital invests in
Countries Arve Capital invests in
Investment Focus
Industry
- Health Care 5 (45%)
- Software 3 (27%)
- Artificial Intelligence 3 (27%)
- Biotechnology 2 (18%)
- Manufacturing 2 (18%)
Stage
- Seed 8 (73%)
- Pre-Seed 2 (18%)
- Funding Round 1 (9%)
Country
- Germany 6 (55%)
- Denmark 1 (9%)
- Switzerland 1 (9%)
- United Kingdom 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kyrok
|
Kyrok is a Berlin-based AI startup focused on supply chain teams in pharma and chemicals, with software for planning, inventory, procurement, and production. It says its tools sit on top of existing ERP systems and aim to reduce manual work and overstock/shortages. | $3.5M / Pre-Seed / Jun 23, 2026 | |
Mirantus Health
|
Mirantus is building a distributed healthcare provider to improve access to care for underserved patients. Through healthcare services (Mirantus Care) and cloud-solutions (Mirantus OS), Mirantus empowers doctors to efficiently treat patients who were difficult to reach before. This improves healthcare access for patients, allows physicians to earnmore, while saving payors billions in downstream costs. Mirantus is on a mission to get every specialist physician in Europe to participate in distributed healthcare, to improve healthcare access for 100M+ underserved patients. | $6.3M / Seed / Nov 20, 2025 | |
StratifAI
|
Building the next generation of biomarkers for precision oncology | $14.7M / Sep 30, 2025 | |
Research Grid (R.grid)
|
R.grid has built machine learning-based software for medical research. | $6.4M / Seed / Nov 06, 2024 | |
|
StratifAI
|
Building the next generation of biomarkers for precision oncology | $1.7M / Pre-Seed / Sep 02, 2024 | |
Vivalyx
|
Vivalyx Omnisol will be a process- and cost-effective one-stop solution for all preservation applications, allowing NMP without the use of blood or human products. | $5.8M / Seed / Apr 30, 2024 | |
IQONIC.AI
|
Creating AI Solutions for Skin, Hair & Inner Balance | Seed / Nov 10, 2023 | |
deepeye
|
deepeye® is a precision medicine platform for retinal diseases. It enables ophthalmologists to provide individual therapy to patients suffering from prevalent eye diseases like Age-related Macular Degeneration (AMD) or other retinal diseases which affect 12% of the EU+US population, thus preventing the causes of more than 66% of blindness'. | $2.7M / Seed / Nov 07, 2023 | |
Biograil
|
Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery ofthe biologic efficiently into the gastrointestinal wall. | Seed / Oct 04, 2022 | |
Avelo
|
Avelo mission is to save lives by bringing fast and actionable infectious disease diagnoses to primary care. | $2.3M / Seed / Sep 20, 2022 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Arve Capital invest in?
Arve Capital invests primarily in Health Care, Software and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 11 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Arve Capital last invest?
The most recent investment recorded for Arve Capital closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
